Physician profile
Michael T Cross
NPI 1316033095
$4,907.71
in general payments reported to CMS, 2019-2025
26 companies · $1,021 in 2025
The $1,021 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $336 · 2020: $343 · 2021: $796 · 2022: $861 · 2023: $968 · 2024: $582 · 2025: $1,021.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,571.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,571.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,025.07 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $639.50 | 2019-2025 | |
| Csl Behring | $621.99 | 2019-2025 | Haegarda, Hizentra |
| Astrazeneca Pharmaceuticals LP | $608.74 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Takeda Pharmaceuticals U.S.A., INC. | $294.44 | 2020-2025 | Takhzyro, Cuvitru, Hyqvia |
| Ars Pharmaceuticals Operations, INC. | $213.93 | 2025 | Neffy |
| Regeneron Healthcare Solutions, INC. | $179.24 | 2021-2025 | Dupixent |
| Pfizer INC. | $165.22 | 2019-2025 | |
| Biocryst US Sales Co., LLC | $143.74 | 2021-2024 | Orladeyo |
| Genentech USA, INC. | $121.96 | 2019-2024 | Xolair |
| Amgen INC. | $120.51 | 2023-2025 | Tezspire |
| Grifols USA, LLC | $115.77 | 2022-2025 | Xembify |
| Pharming Healthcare, INC. | $99.17 | 2020-2025 | Ruconest |
| Hospira, INC. | $98.39 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $75.63 | 2019-2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.05 | 2022-2023 | Spiriva Respimat |
| Teva Pharmaceuticals USA, INC. | $52.40 | 2021 | |
| Alk-Abello, INC | $52.21 | 2019-2020 | |
| Optinose US, INC. | $43.82 | 2019-2021 | |
| Biocryst Pharmaceuticals, INC. | $32.39 | 2020 | |
| Kaleo, INC. | $31.72 | 2021-2023 | Auvi-Q |
| Insmed, INC. | $24.70 | 2025 | Arikayce |
| Paratek Pharmaceuticals, INC. | $23.74 | 2025 | Xhance |
| Cycle Pharmaceuticals INC | $20.40 | 2025 | Sajazir |
| Aimmune Therapeutics, INC. | $19.27 | 2022 | |
| Merck Sharp & Dohme LLC | $16.71 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Cross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.